Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Peter Maybarduk Profile picture
Peter Maybarduk
@Maybarduk
Access to Medicines Director at Public Citizen, Governance Board at Medicines Patent Pool, public interest IP lawyer, songwriter under Creative Commons licenses
Mar 17, 2023 • 11 tweets • 9 min read
Things to know before @SenSanders grills Moderna next week:

First, it's called the "NIH-Moderna" vaccine for a reason.

Moderna received more than $12 billion from taxpayers, including $2.1 billion for R&D & roughly $10bn in advance purchase commitments & purchases.

🧵 1/ From 2020-2022, BARDA (at the Dept of Health & Human Services) provided Moderna with $1.7bn to support clinical trials.

@DeanBaker13 @davidalim @Alexruoff

🧵 2/

investors.modernatx.com/financials/sec…
Jun 29, 2020 • 4 tweets • 2 min read
In an offensive display of hubris and disregard for the public and the pandemic, @GileadSciences has priced at thousands of dollars a drug that should be in the public domain. Gilead’s price is 10x the cost-effective price ($310) suggested by ICER (no mortality benefit) (1/4) For $1 per day, remdesivir can be manufactured at scale with a reasonable profit. According to ICER, at $310 per course, remdesivir would be cost effective. Gilead has rejected both prices and has yet to show why the price should be higher. (2/4) icer-review.org/announcements/…
May 12, 2020 • 6 tweets • 4 min read
Gilead still wants to control remdesivir. @GileadSciences needs to get used to giving up that control. #Remdesivir should be in the public domain (1/6) @Public_Citizen @MSF_access @uaem @OSFHealth Today @GileadSciences announced a deal with five other firms to facilitate remdesivir international manufacture and distribution. The more than 70 countries excluded would have to buy remdesivir from Gilead at its monopoly price, or overcome Gilead’s claimed patents. (2/6)